# Hangzhou Proprium Biotech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hangzhou-proprium-biotech-co

- Industry: Pharmaceuticals
- Headquarters: Hangzhou, China
- Website: www.propriumbio.com
- Latest round: Series A (May 22, 2020)
- Investors on record: 1

## About

Founded in 2010 and based in Hangzhou, China, Hangzhou Proprium Biotech Co., Ltd. operates as a medical company that focuses on the research and development of biopharmaceutical products. It has a clean production laboratory of 3,000 square meters under ISO13485 international certification standards, as well as 50 square meters of class 10,000 clean laboratory operation room, and other equipment and facilities. Biaoyang Lin, a core member of the team, has published more than 90 papers in top journals such as Science, Nature, New England J. Medicine, and PNAS. In 2016, it cooperated with the Pakistan Armed Forces Institute of Pathology. The company was recognized as the National High-tech Enterprise in 2021. In May 2020, Hangzhou Proprium Biotech Co., Ltd. closed a series A funding led by new investor Neovision Capital.

Hangzhou Proprium Biotech Co., Ltd.'s main business is the development, production, and sales of biopharmaceutical field project products. Its products can be categorized into liver disease diagnostic reagents, heart disease diagnostic reagents, infectious disease diagnostic reagents, Liver Disease Net app, and testing instruments. The liver disease diagnostic reagents include colloidal gold rapid diagnostic kits, enzyme immunoassay (Elisa) rapid diagnostic kits, etc.

The company generates revenue by selling biopharmaceutical products for clinical diagnosis.

## Funding rounds

- Series A, May 22, 2020 — Neovision Capital

## Investors

- Neovision Capital (https://capitalatlas.ai/funds/neovision-capital) — Series A